|
Patent landscape, scope, and claims: |
Executive summary
US Patent 8,318,682 is a broad HCV-related small-molecule IP family covering “Formula I” compounds (and pharmaceutically acceptable salts) with extensive substituent variability plus dependent claim scope for specific structural fallbacks (notably Formula II where Y and Y1 are oxygen and X2 is C–R10; and multiple narrow exemplifications such as R6=CN, R5=N3, and ORa substitutions). The claim set spans compound claims, pharmaceutical compositions with optional HCV co-therapies, and method-of-use claims for inhibiting HCV polymerase and treating a multi-virus list including HCV. This breadth drives litigation and generic-entry risk at the compound, formulation, and method-use levels, with the main practical design-around route being to move outside the Formula I/II definition (especially the mandatory R6=CN and the constraints on W1/W2 and the “adjacent carbon” O(CO)O motif or olefin-forming linkage).
United States Patent 8,318,682 scope and claims: Formula I HCV polymerase inhibitors
What is US Patent 8,318,682’s claim scope at a high level?
Primary coverage: a genus of small-molecule compounds defined by a highly parameterized Formula I (plus pharmaceutically acceptable salts), with dependent claims narrowing to sub-genuses (Formula II and specific substituent embodiments).
Claim types included:
- Product (compound) claims: Claim 1 (Formula I genus) and Claim 18 (further “compound that is or a pharmaceutically acceptable salt thereof” coverage).
- Product-by-use claims via formulation: Claim 19 (pharmaceutical composition).
- Combination therapy formulations: Claim 20 (composition with optional additional therapeutic agents).
- Method-of-use claims: Claim 21 (inhibiting HCV polymerase) and Claims 22–24 (treating viral infections, including HCV).
Functional anchor for infringement theories: Claim 21 explicitly recites inhibiting HCV polymerase, giving method-use enforcement hooks even where compound identity is disputed or where use/patient population arguments are central.
Immediate scope bottlenecks in Claim 1 (suitability for freedom-to-operate screens):
- R6 is fixed: “R6 is CN.”
- Adjacency constraint for certain substituents: “or any two R1…R5 on adjacent carbon atoms when taken together are —O(CO)O— or… form a double bond.”
- W1/W2 structural relationship: either (i) W1 and W2 together define a “—Y3(C(Ry)2)3Y3—” motif, or (ii) one with part of ring identity “Formula Ia” or (iii) each independently is Formula Ia.
- R5 has at least one dependent explicit hook: Claim 6 sets R5 = N3, and Claim 7 further specifies X2 is C–H and R3 and R5 are each H (the wording suggests internal conditionality across dependent layers).
- Formula II oxygen-only constraint: Claims 2–4 narrow to Y and Y1 are O and X2 is C–R10, with additional constraints on R8/R9.
How broad is the Formula I genus in Claim 1?
Claim 1 is a combinatorial genus with large permutation capacity across:
- R1–R5 (each independently selected from broad atoms/groups: H, ORa, N(Ra)2, N3, CN, NO2, sulfonyl/sulfonyloxy motifs, halogens, alkyl/carbocyclylalkyl, alkenyl/alkynyl and substituted variants, and aryl(C1–C8)alkyl).
- Ra is independently selected from multiple alkyl/alkenyl/alkynyl/arylalkyl and multiple acyl/oxycarbonyl/thiocarbonyl/sulfonyl and sulfinyl-like moieties (including —C(═O)R11, —C(═O)OR11, —C(═O)NR11R12, —S(O)nR11, —S(O)2R11, —SO2NR11R12).
- R6 is fixed as CN, cutting the genus but still leaving massive room on other positions.
- R7 is defined as one of many substituents including H, acyl/ester/amides/sulfonamides, sulfoxide/sulfone variants, and “Y” is a hetero-atom designation set (O, S, NR, positively charged N(O)(R) etc.).
- W1/W2 and Formula Ia impose ring motif definitions tied to Y1/Y2/Y3 and Rx substituent families.
In practice, this style of genus claim is typically designed to:
- Cover multiple distinct scaffold instances that share the same key fixed functional handles (here, at least R6=CN plus linkage rules for adjacent substituents and the W1/W2 motif definition).
- Permit salts and broad substituent variability to capture marketed analogs.
What specific constraints are “hard” in Claim 1 (most design-around relevant)?
1) Mandatory nitrile:
2) Adjacent substituent linkage rule:
- “any two R1…R5 on adjacent carbon atoms” must be:
- “—O(CO)O—” taken together, or
- taken with their attached ring carbons such that they form “a double bond.”
This creates a structural gating feature. A competitor moving to an adjacent-dicarbonyl/olefin system that does not match those exact combined representations can aim to fall outside Claim 1.
3) W1/W2 motif and Formula Ia routing:
- If W1 and W2 taken together are “—Y3(C(Ry)2)3Y3—” (a repeat unit with terminal heteroatoms Y3), or
- one with R3/R4 forms “—Y3—” and the other is Formula Ia, or
- each is independently Formula Ia.
That logic is designed to lock in a specific ring system or fused heteroaromatic/polyatomic substitution pattern.
4) Ra and R11/R12 are broad but bounded:
- They include multiple functional classes (alkyl, heteroarylalkyl, and carbonyl/sulfonyl/sulfinyl-type moieties) but are still constrained to the enumerated options.
What does dependent Claim 2 narrow in Formula II?
Claim 2 defines the compound according to Claim 1 as Formula II, with:
- X2 is C–R10
- each Y and Y1 is O
This oxygen-only restriction narrows Y heteroatom variability in the ring motif definition.
What does dependent Claim 3 narrow regarding R8?
Claim 3: If Claim 2 applies, then:
- R8 is one of: halogen, NR11R12, N(R11)OR11, NR11NR11R12, OR11, or SR11.
This excludes certain other R8 possibilities that might be present in the larger Rx/R7 definitions (for example, “no” to N3/NO/NO2/CHO/CN type entries as listed in the wider claim drafting).
What does dependent Claim 4 narrow regarding R9?
Claim 4:
This cuts R9 chemical space to a binary selection.
Which dependent claims explicitly pin down substitutions (example set)?
The dependent claims you provided include several “named” points:
- Claim 5: “The compound … wherein R7 is H or …” (the remainder is truncated in your excerpt, so the full alternative is not readable).
- Claim 6: “wherein R5 is N3.”
- Claim 7: “wherein X2 is C—H and R3 and R5 are each H.”
Note: this appears facially inconsistent with Claim 6’s R5=N3 unless read as separate dependent paths; if both are required, there is an internal dependency issue, but the excerpt structure indicates they are separate dependent branches.
- Claim 8: “at least one of R2 or R4 is ORa.”
- Claim 9: detailed “X1 is N or C—R10…” with R10 limited to “H, halogen, CN or optionally substituted heteroaryl.”
- Claim 10: R2 and R4 are each ORa.
- Claim 11: R2 and R4 are each OH.
- Claim 12: R1 is one of H, methyl, CH2OH, CH2F, ethenyl, ethynyl.
- Claim 16: “W1 and W2 are each, independently, a group of Formula Ia.”
- Claim 17: “R7 is H.”
- Claim 18: compound or pharmaceutically acceptable salt.
Across these, the most enforcement-sensitive “fixed” groups for design-around are typically:
- R6=CN
- R2/R4 patterns (ORa or OH in narrower dependents)
- R5 (N3 in Claim 6)
- X1/X2 identities (N vs C–R10; and X2 being C–H in Claim 7 and C–R10 in Claim 2)
How do the composition and combination therapy claims expand enforceability?
Claim 19: pharmaceutical composition
- “A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.”
This covers dosage-form level assets when the active is within Claim 1.
Claim 20: composition with additional therapeutic agent options
Claim 20 adds optional co-therapies, listing classes/agents that align with historical HCV treatment paradigms:
- interferons
- ribavirin analogs
- NS3 protease inhibitors
- NS5a inhibitors
- NS5b polymerase inhibitors
- alpha-glucosidase 1 inhibitors
- cyclophilin inhibitors
- hepatoprotectants
- non-nucleoside inhibitors of HCV
- “other drugs for treating HCV”
For licensing and litigation, Claim 20 matters because it can create additional leverage where a challenger argues that they do not infringe a compound claim but do market a combination regimen that uses a Claim 1 compound.
What method-of-use claims exist for HCV polymerase and treating viruses?
Claim 21: inhibiting HCV polymerase
- “A method of inhibiting HCV polymerase comprising administering… a therapeutically effective amount of a compound of claim 1.”
This supports method-of-use enforcement against conduct, not just product form.
Claims 22–24: treating viral infections
- Claim 22: treating viral infections caused by a list that includes:
dengue, yellow fever, West Nile, Japanese encephalitis, tick-borne encephalitis, Kunjin, Murray Valley encephalitis, St. Louis encephalitis, Omsk hemorrhagic fever, bovine viral diarrhea, Zika, and Hepatitis C virus
- Claim 23: narrows to HCV specifically.
- Claim 24: further adds co-therapy options similar to Claim 20, listing interferons, ribavirin analogs, NS3/NS5a/NS5b inhibitors, alpha-glucosidase 1 inhibitors, cyclophilin inhibitors, hepatoprotectants, non-nucleoside inhibitors, and other HCV drugs.
From a patent landscape perspective, these method claims broaden potential infringement scenarios by aligning to therapeutic indications and combination regimens.
Which viral indications does 8,318,682 cover, and does HCV get special emphasis?
Are HCV indications explicitly core to the patent’s claim set?
Yes. Even though Claim 22 lists a broad multi-virus set, the patent has dedicated HCV-specific enforcement hooks:
- Claim 21 is explicitly “inhibiting HCV polymerase.”
- Claims 23 and 24 focus the viral infection list down to Hepatitis C virus and add HCV co-therapies.
This structure is typical for patents that are scaffolded around an antiviral target (polymerase inhibition) while preserving additional market optionality.
Does the claim language target polymerase or broader antiviral effects?
The method claim is target-specific for Claim 21. Claims 22–24 are treatment-based rather than target-based but still require administering a compound of Claim 1 (or composition of Claim 1).
That means infringement can be argued both as:
- mechanism-linked to HCV polymerase (Claim 21), and
- indication-linked to HCV and viral treatment lists (Claims 22–24).
What formulations are covered: salts, compositions, and combination regimens?
What dosage-form scope is covered by “pharmaceutically acceptable carrier”?
Claim 19 is not limited to a dosage form. It covers any formulation that includes:
- therapeutically effective amount of a Claim 1 compound, plus
- a pharmaceutically acceptable carrier.
This is broad enough to cover oral solids, tablets, capsules, powders, and other common pharmaceutical carriers, depending on what the specification supports (not provided in your excerpt).
What combination therapy scope is covered?
Claim 20 lists multiple co-therapy classes that map to:
- interferon/ribavirin eras,
- direct acting antivirals (NS3 protease inhibitors; NS5a inhibitors; NS5b polymerase inhibitors),
- and additional adjunct classes (cyclophilin inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside HCV inhibitors).
This gives the patent leverage in combination regimen marketing or in settlement contexts where branded combination use is the real-world scenario.
How strong is the patent estate coverage for US 8,318,682: compound genus vs narrow dependents?
What does the claim structure imply about enforceability?
- High genus breadth (Claim 1) increases the chance that future analogs or close variants still fall within the parameterized formula constraints.
- Many dependent claims specify critical substitutions (CN, N3, ORa/OH at certain positions, X1/X2 selections, and W1/W2 handling), giving multiple “landing pads” for claim charting.
- Method claims add conduct leverage beyond product identity.
Where are the likely vulnerability points in a Claim 1 genus?
Even with breadth, genus claims can be attacked on:
- clarity of formula scope (how a competitor interprets substituent and linkage representations),
- enablement written description issues (not assessable from the excerpt),
- and prosecution history estoppel depending on amendment paths (not assessable here).
On infringement, design-around focuses on failing one of the mandatory or rule-driven constraints, particularly R6=CN, W1/W2 motif logic, and the adjacent substituent linkage rule.
What generic entry risks exist under US patent 8,318,682-style claims?
How would a generic or biosimilar-type entrant face risk?
While biosimilars are not relevant to small-molecule compounds, the generic risk analysis is:
- If a generic files an ANDA for an HCV drug product containing an active that falls within Claim 1, it faces potential infringement of the compound and composition claims.
- If the product is not within the compound claims but is used in an HCV regimen matching Claim 21/23, method-of-use enforcement risk depends on how method-of-use claims are treated in the relevant enforcement venue and how “carrying out” the claimed steps occurs in the US market.
What is the most direct design-around strategy for ANDA-like products?
- Avoid the mandatory R6 nitrile pattern (or change it to a non-CN moiety).
- Alter substitution patterns so they do not satisfy the adjacent “—O(CO)O— or double bond” combined representation.
- Break the W1/W2/Formula Ia-defined structural motif.
Those are the structural gating features most useful for claim charts.
How does 8,318,682 compare with other HCV small-molecule patent claim styles?
Without the companion patents in this family, a precise cross-patent comparison is not available. Structurally, however, Claim 1 resembles a common patent drafting strategy in antiviral chemistry:
- “formula-genus” compound claim with broad substituent definitions,
- dependent claim narrowing to specific substituent patterns and specific heteroatom assignments,
- and method-of-use claims that align to an antiviral target and labeled indications.
That drafting increases the number of plausible infringement theories against product and regimen conduct.
Key takeaways
- US Patent 8,318,682 Claim 1 is a broad Formula I genus with extensive substituent variability, but it retains hard constraints, including R6 = CN and linkage/motif rules for adjacent substituents and the W1/W2 system.
- Dependent claims narrow to Formula II with Y and Y1 = O and further pin down substituents like R5 = N3 and R2/R4 as ORa or OH in narrower branches.
- The patent includes composition and combination regimen claims with optional co-therapies spanning interferons, ribavirin analogs, and NS3/NS5a/NS5b inhibitors.
- HCV is specifically emphasized through Claim 21 (HCV polymerase inhibition) and Claims 23–24 (HCV treatment, including combination therapy add-ons).
- Generic-entry risk is highest for competitors that cannot move outside the mandatory structural constraints or that market regimens whose use maps to the method claims.
FAQs
-
What substituent in Claim 1 is mandatory and how does that affect design-around?
R6 is fixed as CN, so switching R6 to a non-nitrile group is a direct route to escape Claim 1.
-
Does the patent protect salts as well as the parent compounds?
Yes. Claims repeatedly cover “a compound … or a pharmaceutically acceptable salt thereof” (Claim 1 and Claim 18).
-
Which dependent claims most strongly narrow the generic design space?
The oxygen-only narrowing of Formula II (Y and Y1 = O) (Claim 2), the substitution restrictions around R8/R9 (Claims 3–4), and pinned substituent selections like R5 = N3 (Claim 6) are the most limiting fallbacks.
-
Are HCV polymerase inhibition and HCV treatment claims separate from compound claims?
Yes. The patent has a compound genus (Claim 1) plus independent method-of-use claims for HCV polymerase inhibition (Claim 21) and HCV treatment (Claims 23–24).
-
Can combination therapy practice increase infringement exposure under this patent?
Yes. Claims 20 and 24 add optional co-therapeutics to composition and method claims, creating additional infringement paths for regimen-based enforcement.
References
- United States Patent 8,318,682. (claims text provided by user).
More… ↓
⤷ Start Trial
|
